Search

Refereed Journals

2021

[275]  
[274]  
[273]

 

[272] Strategies to Combat Multi-Drug Resistance in Tuberculosis. V. Singh and K. Chibale* Acc. Chem. Res. 2021, 54, 2361−2376
[271] Expanding the Activity Profile of Pyrido[1,2‑a]benzimidazoles:Synthesis and Evaluation of Novel N1‑1-Phenylethanamine Derivatives against Schistosoma mansoni. A. Probst, K. Chisanga, G. A. Dziwornu, C. Haeberli, J. Keiser*, and K. Chibale.* ACS Infect. Dis. 2021, 7, 1032−1043
[270] MalDA, accelerating the malaria drug discovery pipeline.  T. Yang, S. Ottilie, E.S. Istvan, K. P. Godinez-Macias, A. Lukens, B. Baragana, B. Campo, C. Walpole, J. Niles, K. Chibale, K. Dechering, M. Llinas, M. Lee, N. Kato, S. Wyllie, C. McNamara, F.-J.B.Gamo, J. Burrows, D. A. Fidock, D. Goldberg, I. Gilbert, D.F. Wirth and,  E. Winzeler.* Trends in Parasitology, 2021, 37 (No. 6/June), 493-507
[269] Developing synergistic drug combinations to restore antibiotic sensitivity in drug-resistant Mycobacterium tuberculosis.  C. Omollo*, V. Singh, E. Kigondu, A. Wasuna, P. Agarwal, A. Moosa, T. Ioerger, V. Mizrahi, K. Chibale, and D. Warner*. Antimicrob. Agents Chemother. 2021, 65, (Issue 5) e02554-20 
[268] Antimalarial Benzimidazole Derivatives Incorporating Phenolic Mannich Base Side Chains inhibit Microtubule and Hemozoin formation: Structure-Activity Relationship and In Vivo Oral Efficacy Studies. G. A. Dziwornu, D. Coertzen, M. Leshabane, C. M. Korkor, C. K. Cloete, M. Njoroge, L. Gibhard, N. Lawrencee, J. Reader, M. van der Watt, S. Wittlin, L.-M. Birkholtz, and K. Chibale.* J. Med. Chem. 2021, 64, 5198−5215
[267] Antiviral Drug Discovery: Preparing for the Next Pandemic.  C. S. Adamson, K. Chibale, R. J. M. Goss, M. Jaspars, D. J. Newman and R. A. Dorrington*.  Chem. Soc. Rev., 2021, 50, 3647–3655, DOI: 10.1039/d0cs01118e 
[266] Plasmodium Kinases as Potential Drug Targets for Malaria: Challenges and Opportunities. L. Arendse*, S. Wyllie, K. Chibale and I.H. Gilbert.* ACS Infect. Dis. 2021, 7, 518−534
[265] New Amidated 3,6-diphenylated Imidazopyridazines with Potent Antiplasmodium Activity are Dual Inhibitors of Plasmodium phosphatidylinositol-4-kinase and cGMP-dependent protein kinase. P. Cheuka, L. Centani, L. Arendse, S. Fienberg, L. Wambua, S. Renga, G. Dziwornu, M. Kumar, N. Lawrence, D. Taylor, S. Wittlin, D. Coertzen, J. Reader, M. van der Watt, L.-M. Birkholtz and K. Chibale.*, ACS Infect. Dis. 2021, 7, 34−46